Raymond James analyst Dane Leone reiterated a Buy rating on RegenXBio (NASDAQ:RGNX) on Wednesday, setting a price target of $60, which is approximately 93.17% above the present share price of $31.06.
Leone expects RegenXBio to post earnings per share (EPS) of -$0.91 for the fourth quarter of 2020.
The current consensus among 5 TipRanks analysts is for a Strong Buy rating of shares in RegenXBio, with an average price target of $64.
The analysts price targets range from a high of $95 to a low of $31.
In its latest earnings report, released on 06/30/2020, the company reported a quarterly revenue of $16.57 million and a net profit of -$41.83 million. The company's market cap is $1.16 billion.
According to TipRanks.com, Raymond James analyst Dane Leone is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 15.1% and a 66.13% success rate.
REGENXBIO, Inc. is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.